Smoking Cessation Programme in Workplaces in Hong Kong (Phase IV)

May 19, 2023 updated by: Dr. Wang Man-Ping, The University of Hong Kong

Assessing the Corporate Environment in Promoting Tobacco Control and Evaluation of a Smoking Cessation Programme in Workplaces in Hong Kong

Smoking causes cardiovascular and respiratory diseases, cancers and diabetes, and it has been a leading risk factor for death globally. Despite the availability of smoking cessation services locally, most smokers do not use such services. Workplace is one of the most convenient platforms to provide smoking cessation services and over 55% of smokers are employed according to the local population-based survey. However, the effectiveness of a smoking cessation programme conducted in workplace is yet to be examined in Hong Kong, and the attitudes and practices of corporations in promoting smoking cessation are not clear. Thus, this study aims to examine the employers'/ managerial staff's knowledge, attitudes and practices in promoting smoking cessation in workplace and evaluate the smoking behaviors of participants before and after attending a smoking cessation intervention.

Study Overview

Detailed Description

This study will separate into two phases. Phase I is a large scale cross-sectional survey to corporations in Hong Kong to examine the employers' knowledge, attitudes and practices in promoting smoking cessation in the workplace. Phase II is a 2-arm randomized controlled trial will be conducted to examine the effectiveness of WhatsApp intervention.

Outcome:

The primary outcome of the study is to measure participated smokers' self reported 7-day point prevalence quit rate at 6-month follow-up. Secondary outcomes include participated smokers' (i) self reported 7-day point prevalence quit rate at 9- and 12-month follow-ups; (ii) self-reported reduction rate at 6-, 9- and 12-month follow-ups; (iii) self-reported quit attempt at 6-, 9- and 12-month follow-ups; (iv) change in self-efficacy towards smoking cessation at 6-, 9- and 12-month follow-ups compared with baseline.

Data analyses

Phase I:

Descriptive statistics will be used to measure the (1) basic information of the corporations, including the total number of employees and smoking employees; (2) knowledge on smoking of employers/managerial staff; (3) attitudes on smoking cessation of employers/managerial staff; (4) practices of the corporations with respect to smoking cessation.

Phase II:

Descriptive statistics such as frequency, percentage, and mean will be used to summarize the outcomes and other variables. Chi-square tests and t-tests will be used to compare outcome variables between subgroups. The intention-to-treat analysis will be used such that those lost to contact and refused cases at the follow-ups will be treated as no reduction in cigarette consumption nor quitting. Subgroup analyses will be conducted among the "adherence" cohort, which is classified as subjects who actively participant in the WhatsApp interaction.

Study Type

Interventional

Enrollment (Actual)

556

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hong Kong, Hong Kong
        • School of Nursing, The University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Hong Kong residents aged 18 or above
  • Smoke at least one cigarette per day
  • Able to communicate in Cantonese/Mandarin and read Chinese
  • Able to use instant messaging tool (e.g. WhatsApp) for communication
  • Stay at Hong Kong during the intervention and follow-up periods (12 months)

Exclusion Criteria:

  • Smokers who are psychologically or physically unable to communicate
  • Currently following other smoking cessation programme(s)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: WhatsApp interaction
Individual and group chat interactions.
Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.
The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
Placebo Comparator: Text message
Regular text messages with similar frequency to those in the Intervention group.
Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
Participants will receive regular text messages with similar frequency to those in the intervention group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-reported 7-day point prevalence quit rate
Time Frame: 6-month
Smokers who did not smoke even a puff in the 7 days preceding the follow-up
6-month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-reported 7-day point prevalence quit rate
Time Frame: 9- and 12-month
Smokers who did not smoke even a puff in the 7 days preceding the follow-up
9- and 12-month
Self-reported reduction rate
Time Frame: 6-, 9-, and 12-month
Smokers' who reduced tobacco use (in term of daily cigarette consumption) in the follow-up when comparing with the baseline
6-, 9-, and 12-month
Biochemical validation of smoking status
Time Frame: 6-, 9-, and 12-month
Biochemically validated quit rate (saliva cotinine level and exhale carbon monoxide test)
6-, 9-, and 12-month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2019

Primary Completion (Actual)

December 31, 2021

Study Completion (Actual)

March 31, 2022

Study Registration Dates

First Submitted

March 10, 2019

First Submitted That Met QC Criteria

March 10, 2019

First Posted (Actual)

March 12, 2019

Study Record Updates

Last Update Posted (Actual)

May 22, 2023

Last Update Submitted That Met QC Criteria

May 19, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • LST SCPW P4

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Smoking Cessation

Clinical Trials on Occupational-specific health talk

Subscribe